Disulfide isoform modulation
By regulating the disulfide subtype of recombinant proteins through contact with reducing agents or oxidizing agents, the problem of inconsistent disulfide structure distribution in existing technologies is solved, thereby improving the bioactivity and therapeutic efficacy of the IgG2 subclass.
Patent Information
- Authority / Receiving Office
- CN Β· China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-10
- Publication Date
- 2026-07-10
AI Technical Summary
Existing technologies struggle to effectively regulate the distribution of disulfide subtypes in recombinant proteins, leading to inconsistent biological activities. In particular, the IgG2 subclass exhibits low affinity for the Fc receptor, impacting the efficacy of therapeutic antibodies.
The distribution of disulfide isoforms of recombinant proteins can be regulated by contacting them with reducing or oxidizing agents. Specific methods include using reducing agents to increase the proportion of IgG2-B isoforms during culture or using oxidizing agents to maintain the amount of existing isoforms.
This study optimized and improved the bioactivity and consistency of recombinant proteins, enhanced the affinity of IgG2 subclasses for Fc receptors, and improved the biotherapeutic effect of therapeutic antibodies.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3